Diagnostic News and Research

RSS

Definiens closes €15M financing round to expand into digital tissue diagnostics

Definiens AG, which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment, said that it has closed a round of financing for € 15 million.

23 Jun 2014

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results.

20 Jun 2014

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics.

20 Jun 2014

Researchers review effectiveness of RDTs in diagnosing visceral leishmaniasis

Researchers from the Cochrane Infectious Disease Group, co-ordinated through the editorial base in LSTM, conducted an independent review into the effectiveness of rapid diagnostic tests in diagnosing patients with visceral leishmaniasis (VL), published in The Cochrane Library today.

20 Jun 2014

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

According the World Health Organization, such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease. That is why numerous scientists around the world have invested a great deal of effort in understanding these diseases. Yet the molecular and cellular mechanisms that underlie these problems are still only partly understood.

20 Jun 2014

Patients in new DSM-5 bipolar category ‘deserve attention’

People who fall into the DSM-5 Other Specified Bipolar and Related Disorders category carry a significant clinical burden, a study shows.

19 Jun 2014

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

19 Jun 2014

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.

19 Jun 2014

Electroanalysis journal publishes a special issue about clinical diagnostics

The demand for the development of novel diagnostic tools with interest for clinical analysis is increasing.

19 Jun 2014

Electroanalysis journal publishes a special issue about clinical diagnostics

The demand for the development of novel diagnostic tools with interest for clinical analysis is increasing.

19 Jun 2014

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla.

18 Jun 2014

Scientists demonstrate that proteins in urine play important role in stress incontinence

Incontinence is the world's most common chronic condition. Around ten per cent of Austrians are affected by it. However the problem continues to be a taboo subject: two out of three sufferers do not talk about it, preventing access to successful treatment.

18 Jun 2014

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

Eden licenses Sandia’s technology to develop radioactive isotope for medical diagnostic tests

An Albuquerque startup company has licensed a Sandia National Laboratories technology that offers a way to make molybdenum-99, a key radioactive isotope needed for diagnostic imaging in nuclear medicine, in the United States.

18 Jun 2014

New project improves techniques for detecting E. coli

Kansas State University diagnosticians are helping the cattle industry save millions of dollars each year by developing earlier and accurate detection of E. coli.

17 Jun 2014

Five specific tests commonly performed in anesthesiology may not be necessary

Proving that less really is more, five specific tests or procedures commonly performed in anesthesiology that may not be necessary and, in some cases should be avoided, will be published online June 16 in JAMA Internal Medicine.

17 Jun 2014

Parents value convenience of sports physicals but recognize importance of thorough doctor visits

Nearly half of parents say any qualified health care provider - not just a child's usual provider - can do a sports physical, according to a new University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health.

17 Jun 2014

Promising way to prevent disparities in colorectal cancer screening

People living in poverty are less likely to be screened regularly for colorectal cancer-and more likely to develop the disease and die from it. How to end these disparities-and raise screening rates, lower disease rates, and prevent deaths? A promising way is to mail fecal immunochemical tests (a newer kind of stool test) to populations, Beverly B. Green, MD, MPH, and Gloria D. Coronado, PhD, wrote in the June 17 JAMA Internal Medicine.

17 Jun 2014

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Cepheid today announced the release of Xpert® Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices.

16 Jun 2014